This company listing is no longer active
Codiak BioSciences (CDAK.Q) Stock Overview
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
CDAK.Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Codiak BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0016 |
| 52 Week High | US$3.09 |
| 52 Week Low | US$0.0016 |
| Beta | 3.43 |
| 1 Month Change | -82.22% |
| 3 Month Change | -92.00% |
| 1 Year Change | -99.95% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Brokers Are Upgrading Their Views On Codiak BioSciences, Inc. (NASDAQ:CDAK) With These New Forecasts
Nov 08
Codiak BioSciences drops 31% postmarket on proposed stock offering
Sep 12Recent updates
Brokers Are Upgrading Their Views On Codiak BioSciences, Inc. (NASDAQ:CDAK) With These New Forecasts
Nov 08Codiak BioSciences drops 31% postmarket on proposed stock offering
Sep 12Codiak cuts 37% of staff amid plans to reprioritize studies
Aug 30Codiak begins dosing in early-stage trial for liver, gastric, colorectal cancers
Jun 29Broker Revenue Forecasts For Codiak BioSciences, Inc. (NASDAQ:CDAK) Are Surging Higher
Mar 15Codiak BioSciences, Inc. (NASDAQ:CDAK) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Insider Buying: The Codiak BioSciences, Inc. (NASDAQ:CDAK) Independent Director Just Bought US$100k Worth Of Shares
Feb 18
What Percentage Of Codiak BioSciences, Inc. (NASDAQ:CDAK) Shares Do Insiders Own?
Jan 14Shareholder Returns
| CDAK.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -77.1% | 3.5% | 1.2% |
| 1Y | -99.9% | 3.1% | 16.3% |
Return vs Industry: CDAK.Q underperformed the US Biotechs industry which returned 2.5% over the past year.
Return vs Market: CDAK.Q underperformed the US Market which returned 12.6% over the past year.
Price Volatility
| CDAK.Q volatility | |
|---|---|
| CDAK.Q Average Weekly Movement | 61.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CDAK.Q's share price has been volatile over the past 3 months.
Volatility Over Time: CDAK.Q's weekly volatility has increased from 36% to 62% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 102 | n/a | www.codiakbio.com |
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines.
Codiak BioSciences, Inc. Fundamentals Summary
| CDAK.Q fundamental statistics | |
|---|---|
| Market cap | US$58.93k |
| Earnings (TTM) | -US$17.42m |
| Revenue (TTM) | US$34.07m |
Is CDAK.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDAK.Q income statement (TTM) | |
|---|---|
| Revenue | US$34.07m |
| Cost of Revenue | US$54.81m |
| Gross Profit | -US$20.74m |
| Other Expenses | -US$3.32m |
| Earnings | -US$17.42m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | -60.89% |
| Net Profit Margin | -51.13% |
| Debt/Equity Ratio | 66.0% |
How did CDAK.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/11 17:18 |
| End of Day Share Price | 2023/07/06 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Codiak BioSciences, Inc. is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maneka Mirchandaney | Evercore ISI |
| Graig Suvannavejh | Goldman Sachs |
| David Nierengarten | Wedbush Securities Inc. |